Results 91 to 100 of about 5,328 (181)

Rapidly Growing ALK‐Negative NTRK3‐Positive Inflammatory Myofibroblastic Tumour of the Lung

Respirology Case Reports, Volume 13, Issue 12, December 2025.
This report describes the importance of comprehensive molecular testing in anaplastic lymphoma kinase‐negative inflammatory myofibroblastic tumour (IMT) and demonstrates that complete surgical resection can achieve excellent outcomes even in rapidly growing IMT.
Yukitaka Sato, Fumitsugu Kojima, Takeshi Ushigusa, Shinsaku Kabemura, Torahiko Jinta, Toru Bando   +5 more
wiley   +1 more source

Targeting NGF but not VEGFR1 or BDNF signaling reduces endometriosis-associated pain in mice

Journal of Advanced Research
Introduction: Endometriosis is a chronic inflammatory disease that affects ∼10 % of women. A significant fraction of patients experience limited or no efficacy with current therapies.
Tiago H. Zaninelli, Victor Fattori, Olivia K. Heintz, Kristeena R. Wright, Philip R. Bennallack, Danielle Sim, Hussain Bukhari, Kathryn L. Terry, Allison F. Vitonis, Stacey A. Missmer, Avacir C. Andrello, Raymond M. Anchan, Stephen K. Godin, Dara Bree, Waldiceu A. Verri Jr., Michael S. Rogers   +15 more
doaj   +1 more source

Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model [PDF]

Genomic rearrangements of the neurotrophic receptor tyrosine kinase genes (NTRK1, NTRK2, and NTRK3) are the most common mechanism of oncogenic activation for this family of receptors, resulting in sustained cancer cell proliferation.
Britschgi, Christian, Chen, Yanjiang, Haberecker, Martina, Hagedorn, Catherine, Kollar, Sarah, Pauli, Chantal, Planas-Paz, Lara, Pliego-Mendieta, Alicia, Plock, Jan, Steiner, Sabrina   +9 more
core   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, Volume 19, Issue 11, Page 3023-3034, November 2025.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Secretory breast carcinoma: morphologic and molecular heterogeneity with indicators of aggressive potential in a cohort of 29 cases

The Journal of Pathology: Clinical Research, Volume 11, Issue 6, November 2025.
Abstract Secretory breast carcinoma (SBC) is a rare tumour defined by ETV6‐NTRK3 rearrangement, but its clinicopathological spectrum and potential for aggressive behaviour remain incompletely characterised. We retrospectively reviewed 29 SBCs diagnosed between 2014 and 2024, including 28 females and one male aged 12–63 years (median 44).
Huayan Ren, Wanting Tong, Jiayue Ma, Xinyan Chen, Huifen Huang, Na Wei, Yuqiong Liu, Minglei Yang, Lan Zhang, Huixiang Li   +9 more
wiley   +1 more source

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Therapeutics and Clinical Risk Management, 2018
Dazhi Liu,1 Michael Offin,2 Stephen Harnicar,1 Bob T Li,2 Alexander Drilon2 1Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine ...
Liu D, Offin M, Harnicar S, Li BT, Drilon A   +4 more
doaj  

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

Frontiers in Oncology
The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance.
Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai   +9 more
doaj   +1 more source

Entrectinib Shows Pediatric Potential [PDF]

Cancer Discovery, 2019
Abstract According to preliminary data from the phase I/Ib STARTRK-NG trial, the investigational multikinase inhibitor entrectinib showed efficacy in children and adolescents with CNS and other tumor types harboring NTRK1/2/3, ROS1, or ALK fusions. Durable responses were seen even in CNS tumors such as high-grade glioma.
openaire   +1 more source

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 [PDF]

, 2019
Background Entrectinib is a potent inhibitor of ROS1 (in addition to TRKA/B/C), designed to effectively penetrate the central nervous system (CNS); brain metastases are common in patients with advanced ROS1 fusion-positive NSCLC.
A. Drilon, Byoung Chul Cho, C-C. Lin, C. Ye, Christian Rolfo, D.S.W. Tan, F. de Braud, Fabrice Barlesi, H.-T. Arkenau, Juergen Wolf, Matthew G Krebs, Myung-Ju Ahn, Rafal Dziadziuszko, Robert C. Doebele, Salvatore Siena, Susan Eng, Takashi Seto, Thomas John, Todd Riehl   +18 more
core   +1 more source

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

Expert Opinion on Investigational Drugs, 2015
Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation. In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only ...
Rolfo, Christian, Ruiz, Rossana, Giovannetti, Elisa, Gil-Bazo, Ignacio, Russo, Antonio, Passiglia, Francesco, Giallombardo, Marco, Peeters, Marc, Raez, Luis   +8 more
openaire   +4 more sources